Intrinsic value of Evolent Health Cl A - EVH

Previous Close

$24.96

  Intrinsic Value

$66.38

stock screener

  Rating & Target

str. buy

+166%

Previous close

$24.96

 
Intrinsic value

$66.38

 
Up/down potential

+166%

 
Rating

str. buy

We calculate the intrinsic value of EVH stock by summing up the current values of future distributable cash flows generated by the company and dividing the sum by the number of outstanding shares. As such, the intrinsic value calculation depends entirely on projections. The more accurate your projections of the company's performance are - the more reliable is the intrinsic value calculation result. Please make sure to check the stock valuation input data below and adjust it if necessary. The quality of the output (intrinsic valuation result) is only as good as the quality of the input. See also DISCLAIMERS.

STOCK VALUATION INPUT DATA

Revenue (in 0001), $M
Initial revenue growth rate, %
Terminal revenue growth rate, %
Revenue decline factor
Initial discount rate, %
Discount rate multiplier
Variable cost ratio, %
Fixed operating expenses, $M
Interest rate on debt, %
Effective corporate tax rate, %
Production assets / Revenue, %
Life of production assets, yrs
Working capital / Revenue, %
Revenue / Adjusted assets
Adjusted equity ratio
Cash flow adjustment, % of Revenue
Book value of equity, $M
Shares outstanding, mln
Market capitalization, $bln 1.9

 

FINANCIAL STATEMENTS FORECAST and PRESENT VALUE CALCULATION

Fiscal year
   2
   3
   4
   5
   6
   7
   8
   9
   10
   11
   12
   13
   14
   15
   16
   17
   18
   19
   20
   21
   22
   23
   24
   25
   26
   27
   28
   29
   30
   31

INCOME STATEMENT

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Revenue growth rate, %
  31.50
  28.85
  26.47
  24.32
  22.39
  20.65
  19.08
  17.67
  16.41
  15.27
  14.24
  13.32
  12.48
  11.74
  11.06
  10.46
  9.91
  9.42
  8.98
  8.58
  8.22
  7.90
  7.61
  7.35
  7.11
  6.90
  6.71
  6.54
  6.39
  6.25
Revenue, $m
  572
  737
  932
  1,159
  1,418
  1,711
  2,037
  2,397
  2,791
  3,217
  3,675
  4,164
  4,684
  5,234
  5,813
  6,421
  7,057
  7,722
  8,415
  9,137
  9,888
  10,669
  11,481
  12,325
  13,202
  14,113
  15,060
  16,045
  17,070
  18,137
Variable operating expenses, $m
  195
  226
  263
  306
  355
  410
  472
  540
  615
  695
  695
  787
  886
  990
  1,099
  1,214
  1,335
  1,460
  1,591
  1,728
  1,870
  2,018
  2,171
  2,331
  2,496
  2,669
  2,848
  3,034
  3,228
  3,430
Fixed operating expenses, $m
  413
  422
  431
  441
  450
  460
  470
  481
  491
  502
  513
  525
  536
  548
  560
  572
  585
  598
  611
  624
  638
  652
  666
  681
  696
  711
  727
  743
  759
  776
Total operating expenses, $m
  608
  648
  694
  747
  805
  870
  942
  1,021
  1,106
  1,197
  1,208
  1,312
  1,422
  1,538
  1,659
  1,786
  1,920
  2,058
  2,202
  2,352
  2,508
  2,670
  2,837
  3,012
  3,192
  3,380
  3,575
  3,777
  3,987
  4,206
Operating income, $m
  -36
  89
  238
  412
  613
  840
  1,095
  1,376
  1,685
  2,019
  2,467
  2,852
  3,262
  3,696
  4,154
  4,634
  5,138
  5,664
  6,213
  6,785
  7,380
  8,000
  8,644
  9,313
  10,009
  10,733
  11,485
  12,268
  13,083
  13,931
EBITDA, $m
  73
  204
  361
  544
  755
  993
  1,261
  1,556
  1,880
  2,231
  2,609
  3,014
  3,444
  3,900
  4,379
  4,884
  5,412
  5,964
  6,540
  7,140
  7,764
  8,414
  9,089
  9,792
  10,522
  11,281
  12,070
  12,891
  13,746
  14,635
Interest expense (income), $m
  0
  7
  12
  18
  25
  34
  43
  54
  66
  80
  95
  111
  128
  146
  165
  186
  208
  230
  254
  279
  305
  332
  360
  389
  420
  451
  484
  518
  553
  590
  629
Earnings before tax, $m
  -43
  77
  220
  387
  579
  797
  1,040
  1,310
  1,605
  1,925
  2,356
  2,725
  3,116
  3,531
  3,968
  4,427
  4,907
  5,410
  5,934
  6,480
  7,048
  7,640
  8,254
  8,893
  9,558
  10,249
  10,967
  11,715
  12,492
  13,302
Tax expense, $m
  0
  21
  59
  104
  156
  215
  281
  354
  433
  520
  636
  736
  841
  953
  1,071
  1,195
  1,325
  1,461
  1,602
  1,750
  1,903
  2,063
  2,229
  2,401
  2,581
  2,767
  2,961
  3,163
  3,373
  3,592
Net income, $m
  -43
  56
  160
  282
  423
  582
  759
  956
  1,171
  1,405
  1,720
  1,989
  2,275
  2,577
  2,896
  3,231
  3,582
  3,949
  4,332
  4,730
  5,145
  5,577
  6,026
  6,492
  6,977
  7,482
  8,006
  8,552
  9,119
  9,711

BALANCE SHEET

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Cash and short-term investments, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Total assets, $m
  1,478
  1,904
  2,408
  2,994
  3,664
  4,421
  5,264
  6,195
  7,211
  8,312
  9,496
  10,760
  12,104
  13,524
  15,020
  16,591
  18,235
  19,953
  21,744
  23,610
  25,551
  27,569
  29,667
  31,847
  34,113
  36,467
  38,915
  41,460
  44,108
  46,864
Adjusted assets (=assets-cash), $m
  1,478
  1,904
  2,408
  2,994
  3,664
  4,421
  5,264
  6,195
  7,211
  8,312
  9,496
  10,760
  12,104
  13,524
  15,020
  16,591
  18,235
  19,953
  21,744
  23,610
  25,551
  27,569
  29,667
  31,847
  34,113
  36,467
  38,915
  41,460
  44,108
  46,864
Revenue / Adjusted assets
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
  0.387
Average production assets, $m
  631
  813
  1,028
  1,278
  1,564
  1,887
  2,247
  2,644
  3,078
  3,548
  4,053
  4,593
  5,167
  5,773
  6,412
  7,082
  7,784
  8,517
  9,282
  10,078
  10,907
  11,768
  12,664
  13,594
  14,561
  15,566
  16,611
  17,698
  18,828
  20,005
Working capital, $m
  -99
  -127
  -161
  -200
  -245
  -296
  -352
  -415
  -483
  -557
  -636
  -720
  -810
  -905
  -1,006
  -1,111
  -1,221
  -1,336
  -1,456
  -1,581
  -1,711
  -1,846
  -1,986
  -2,132
  -2,284
  -2,442
  -2,605
  -2,776
  -2,953
  -3,138
Total debt, $m
  216
  330
  465
  622
  802
  1,004
  1,230
  1,480
  1,752
  2,047
  2,364
  2,703
  3,063
  3,444
  3,845
  4,266
  4,707
  5,167
  5,647
  6,147
  6,667
  7,208
  7,770
  8,355
  8,962
  9,593
  10,249
  10,931
  11,641
  12,379
Total liabilities, $m
  396
  510
  645
  802
  982
  1,185
  1,411
  1,660
  1,933
  2,228
  2,545
  2,884
  3,244
  3,624
  4,025
  4,446
  4,887
  5,347
  5,827
  6,327
  6,848
  7,389
  7,951
  8,535
  9,142
  9,773
  10,429
  11,111
  11,821
  12,560
Total equity, $m
  1,082
  1,394
  1,763
  2,192
  2,682
  3,236
  3,854
  4,535
  5,279
  6,085
  6,951
  7,877
  8,860
  9,900
  10,995
  12,144
  13,348
  14,605
  15,917
  17,282
  18,703
  20,181
  21,716
  23,312
  24,970
  26,694
  28,486
  30,349
  32,287
  34,305
Total liabilities and equity, $m
  1,478
  1,904
  2,408
  2,994
  3,664
  4,421
  5,265
  6,195
  7,212
  8,313
  9,496
  10,761
  12,104
  13,524
  15,020
  16,590
  18,235
  19,952
  21,744
  23,609
  25,551
  27,570
  29,667
  31,847
  34,112
  36,467
  38,915
  41,460
  44,108
  46,865
Debt-to-equity ratio
  0.200
  0.240
  0.260
  0.280
  0.300
  0.310
  0.320
  0.330
  0.330
  0.340
  0.340
  0.340
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.350
  0.360
  0.360
  0.360
  0.360
  0.360
  0.360
  0.360
  0.360
  0.360
  0.360
  0.360
Adjusted equity ratio
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732
  0.732

CASH FLOW

 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Net income, $m
  -43
  56
  160
  282
  423
  582
  759
  956
  1,171
  1,405
  1,720
  1,989
  2,275
  2,577
  2,896
  3,231
  3,582
  3,949
  4,332
  4,730
  5,145
  5,577
  6,026
  6,492
  6,977
  7,482
  8,006
  8,552
  9,119
  9,711
Depreciation, amort., depletion, $m
  109
  116
  123
  132
  142
  153
  166
  180
  195
  212
  143
  162
  182
  203
  226
  249
  274
  300
  327
  355
  384
  414
  446
  479
  513
  548
  585
  623
  663
  704
Funds from operations, $m
  67
  172
  284
  414
  565
  735
  926
  1,136
  1,367
  1,617
  1,863
  2,151
  2,457
  2,781
  3,122
  3,481
  3,856
  4,249
  4,658
  5,085
  5,529
  5,991
  6,472
  6,971
  7,490
  8,030
  8,591
  9,175
  9,782
  10,415
Change in working capital, $m
  -24
  -29
  -34
  -39
  -45
  -51
  -56
  -62
  -68
  -74
  -79
  -85
  -90
  -95
  -100
  -105
  -110
  -115
  -120
  -125
  -130
  -135
  -140
  -146
  -152
  -158
  -164
  -170
  -177
  -185
Cash from operations, $m
  90
  200
  317
  453
  610
  786
  982
  1,199
  1,435
  1,691
  1,942
  2,235
  2,547
  2,876
  3,222
  3,586
  3,966
  4,364
  4,778
  5,210
  5,659
  6,126
  6,612
  7,117
  7,642
  8,187
  8,755
  9,345
  9,960
  10,599
Maintenance CAPEX, $m
  -17
  -22
  -29
  -36
  -45
  -55
  -66
  -79
  -93
  -108
  -125
  -143
  -162
  -182
  -203
  -226
  -249
  -274
  -300
  -327
  -355
  -384
  -414
  -446
  -479
  -513
  -548
  -585
  -623
  -663
New CAPEX, $m
  -151
  -182
  -215
  -250
  -286
  -323
  -360
  -397
  -434
  -470
  -505
  -540
  -573
  -606
  -639
  -670
  -702
  -733
  -765
  -796
  -829
  -862
  -896
  -931
  -967
  -1,005
  -1,045
  -1,087
  -1,130
  -1,176
Cash from investing activities, $m
  -168
  -204
  -244
  -286
  -331
  -378
  -426
  -476
  -527
  -578
  -630
  -683
  -735
  -788
  -842
  -896
  -951
  -1,007
  -1,065
  -1,123
  -1,184
  -1,246
  -1,310
  -1,377
  -1,446
  -1,518
  -1,593
  -1,672
  -1,753
  -1,839
Free cash flow, $m
  -78
  -4
  74
  167
  278
  408
  555
  722
  908
  1,112
  1,312
  1,553
  1,812
  2,088
  2,380
  2,690
  3,015
  3,357
  3,714
  4,087
  4,476
  4,881
  5,302
  5,740
  6,196
  6,670
  7,162
  7,674
  8,206
  8,760
Issuance/(repayment) of debt, $m
  94
  114
  135
  157
  180
  203
  226
  249
  272
  295
  317
  339
  360
  381
  401
  421
  441
  460
  480
  500
  520
  541
  562
  584
  607
  631
  656
  682
  710
  739
Issuance/(repurchase) of shares, $m
  302
  256
  208
  146
  68
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash from financing (excl. dividends), $m  
  396
  370
  343
  303
  248
  203
  226
  249
  272
  295
  317
  339
  360
  381
  401
  421
  441
  460
  480
  500
  520
  541
  562
  584
  607
  631
  656
  682
  710
  739
Total cash flow (excl. dividends), $m
  318
  366
  417
  471
  526
  610
  782
  972
  1,180
  1,407
  1,629
  1,892
  2,172
  2,468
  2,781
  3,111
  3,456
  3,817
  4,194
  4,587
  4,996
  5,422
  5,864
  6,325
  6,803
  7,301
  7,818
  8,356
  8,916
  9,499
Retained Cash Flow (-), $m
  -302
  -312
  -369
  -429
  -491
  -554
  -618
  -681
  -744
  -806
  -866
  -926
  -983
  -1,040
  -1,095
  -1,150
  -1,204
  -1,257
  -1,311
  -1,366
  -1,421
  -1,477
  -1,536
  -1,596
  -1,658
  -1,724
  -1,792
  -1,863
  -1,938
  -2,017
Prev. year cash balance distribution, $m
  188
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash flow adjustment, $m
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
  0
Cash available for distribution, $m
  205
  54
  48
  42
  35
  57
  164
  290
  436
  601
  763
  966
  1,188
  1,428
  1,686
  1,961
  2,252
  2,560
  2,883
  3,221
  3,575
  3,944
  4,329
  4,729
  5,145
  5,577
  6,026
  6,493
  6,977
  7,481
Discount rate, %
  4.30
  4.52
  4.74
  4.98
  5.23
  5.49
  5.76
  6.05
  6.35
  6.67
  7.00
  7.35
  7.72
  8.11
  8.51
  8.94
  9.39
  9.86
  10.35
  10.87
  11.41
  11.98
  12.58
  13.21
  13.87
  14.56
  15.29
  16.05
  16.86
  17.70
PV of cash for distribution, $m
  196
  50
  42
  35
  27
  41
  111
  182
  251
  315
  362
  412
  452
  480
  495
  498
  490
  471
  444
  409
  370
  327
  284
  241
  200
  163
  129
  100
  76
  56
Current shareholders' claim on cash, %
  84.0
  74.8
  69.4
  66.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5
  65.5

Evolent Health, Inc. is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company's platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models. The Company's services include providing its customers, with a population management platform, integrated data and analytics capabilities, pharmacy benefit management (PBM) services and comprehensive health plan administration services. Its value-based operations are empowered and supported by Identifi. Identifi is the Company's technology platform that aggregates and analyzes data, manages care workflows and engages patients.

FINANCIAL RATIOS  of  Evolent Health Cl A (EVH)

Valuation Ratios
P/E Ratio -10.6
Price to Sales 6.7
Price to Book 2.4
Price to Tangible Book
Price to Cash Flow -47.1
Price to Free Cash Flow -32.6
Growth Rates
Sales Growth Rate 161.9%
Sales - 3 Yr. Growth Rate %
EPS Growth Rate %
EPS - 3 Yr. Growth Rate %
Capital Spending Gr. Rate 128.6%
Cap. Spend. - 3 Yr. Gr. Rate 9.9%
Financial Strength
Quick Ratio NaN
Current Ratio 0.3
LT Debt to Equity 17.1%
Total Debt to Equity 17.1%
Interest Coverage 0
Management Effectiveness
Return On Assets -14.4%
Ret/ On Assets - 3 Yr. Avg. 4.2%
Return On Total Capital -21.7%
Ret/ On T. Cap. - 3 Yr. Avg. 9.3%
Return On Equity -23.7%
Return On Equity - 3 Yr. Avg. 8.7%
Asset Turnover 0.2
Profitability Ratios
Gross Margin 39%
Gross Margin - 3 Yr. Avg. 26.4%
EBITDA Margin -87%
EBITDA Margin - 3 Yr. Avg. 91.3%
Operating Margin -93.7%
Oper. Margin - 3 Yr. Avg. 96.3%
Pre-Tax Margin -93.7%
Pre-Tax Margin - 3 Yr. Avg. 86.6%
Net Profit Margin -63%
Net Profit Margin - 3 Yr. Avg. 93.1%
Effective Tax Rate 4.6%
Eff/ Tax Rate - 3 Yr. Avg. 3.8%
Payout Ratio 0%

EVH stock valuation input parameters

Revenue. Company's revenue (or sales) is always the starting point of any cash flow forecast. In the EVH stock intrinsic value calculation we used $434.95 million for the last fiscal year's total revenue generated by Evolent Health Cl A. The default revenue input number comes from 0001 income statement of Evolent Health Cl A. You may change it if you feel that it should be adjusted for some unusual circumstances that are not expected to be repeated in the future or if you already know (from interim financial statements, for example) that this year's revenue is going to be quite different.

Revenue growth rate. Forecasted future revenue growth rate is the most important input parameter for the intrinsic value calculation. Unlike other input parameters that are reasonably expected to be in line with their historic averages or their historic trends, the revenue growth rate by and large is a wild card: nobody really knows what the company's revenue will be in the future. Of course, the level of unpredictability is different for different industries (utility companies being the most predictable and, thus, less risky).
    We use three input parameters to forecast the revenue growth rate in our EVH stock valuation model: a) initial revenue growth rate of 31.5% whose default value is the revenue growth rate in the most recent quarter compared to the quarterly revenue a year ago; b) terminal revenue growth rate of 5% whose default value is chosen to be close to the average nominal (i.e. not adjusted for inflation) GDP growth rate; and c) revenue decline factor of 0.9, which stipulates that revenue growth rate in each forecasted year will be equal to the difference of the revenue growth rate in the preceding year and the terminal revenue growth rate multiplied by this revenue decline factor (with the passage of time the revenue growth rate will be approaching the terminal revenue growth rate, but not quite reaching it - though the difference could be infinitesimally small).
    At the revenue decline factor of 1, the future revenue growth rate is forecasted to be constant and equal to the initial revenue growth rate. The smaller the revenue decline factor, the faster the revenue growth rate will approach the terminal revenue growth.

Discount rate. The discount rate is used for determining the present value of future cash flows: future cash flows are "discounted" as at normal conditions (that translate into positive expected return on investment) one dollar today is worth more than the same dollar in the future. Unlike all other valuation models, we use variable discount rate, i.e. it increases for each consecutive year. This is done to account for higher risk of cash flows coming in further in the future.
    The initial discount rate of 4.3%, whose default value for EVH is calculated based on our internal credit rating of Evolent Health Cl A, is applied to the cash flow expected to be received a year from now (well, actually, to be precise, in the financial year following the base year - the last year for which we have financial statements). For each consecutive year the discount rate is multiplied by the discount rate multiplier of 1.05, e.i. each year it increases by 5%. Feel free to change this number to correspond to your level of risk assessment of Evolent Health Cl A.
    By the way, it is easy to set the discount rate to be constant (this would make comparison with other valuation models easier): just set the discount rate multiplier equal to 1 and chose the magnitude of the initial discount rate to your liking.

Variable cost ratio is the ratio of variable costs (i.e. costs that fluctuate with fluctuation of the volume of production) to the revenue expressed as a percentage. In the calculation of intrinsic value of EVH stock the variable cost ratio is equal to 38.9%.

Fixed operating expenses is just that - expenses that are not dependant on the volume of production. They are set to $404 million in the base year in the intrinsic value calculation for EVH stock. These expenses increase with the level of inflation in subsequent years.

Interest rate on debt is the average all-in rate of interest paid by the company on its debt. It is set at 5.4% for Evolent Health Cl A.

Corporate tax rate of 27% is the nominal tax rate for Evolent Health Cl A. In reality, companies find ways to pay much less taxes than that or not to pay them at all.

Cash flow adjustment could be used for any adjustment the investor deems necessary. Most commonly we use this field to account for stock options-related effects in excess of what is reported on the company's income statement. The cash flow adjustment is expressed as a percentage of the revenue, and in the current valuation of the EVH stock is equal to 0%.

Production assets are the company's assets used for manufacturing products or provision of services. In the valuation model input table they are expressed as a percentage of revenue and for EVH are equal to 110.3%.

Life of production assets of 28.4 years is the average useful life of capital assets used in Evolent Health Cl A operations. It is used to calculate yearly capital expenditures needed to keep these assets in good order - we call it the maintenance CAPEX.

Working capital is the difference between the company's current assets and liabilities. In the model we use the ratio of working capital to revenue, which for EVH is equal to -17.3%. A negative number means that the company is apt at using financial resources of its suppliers and customers; a large positive number, on the other hand, means that it either provides in-kind financing to others or is not good at managing its inventories.

Book value of equity - $1010.879 million for Evolent Health Cl A - is used in calculation of the "floor" for intrinsic valuation based on the discounted cash flow (DCF) method. Even if the prospects are very bad for a company, its assets could always be sold now for their current fair market value.

Shares outstanding of 77.88 million for Evolent Health Cl A is needed to calculate the intrinsic value of one share.

Market capitalization is used here only for reference purposes and as a quick check that the share price and the number of shares outstanding numbers are correct - something especially to be cognizant about at stock splits. So, the market capitalization of Evolent Health Cl A at the current share price and the inputted number of shares is $1.9 billion.

RELATED COMPANIES Price Int.Val. Rating
CIVI Civitas Soluti 14.61 28.34  str.buy
LHCG LHC Group 96.19 108.29  hold
CHE Chemed 310.56 169.47  sell
AMED Amedisys 121.99 89.13  sell

COMPANY NEWS

▶ Evolent Health: 3Q Earnings Snapshot   [05:11PM  Associated Press]
▶ Is Evolent Health Incs (NYSE:EVH) CEO Pay Justified?   [Aug-14-18 08:52AM  Simply Wall St.]
▶ Evolent Health: 2Q Earnings Snapshot   [05:20PM  Associated Press]
▶ Markets Are Weak So Far, and So Is Fiat Chrysler   [Jul-23-18 12:37PM  TheStreet.com]
▶ What Is Evolent Health Incs (NYSE:EVH) Share Price Doing?   [Jun-26-18 12:40PM  Simply Wall St.]
▶ Medical Software Rallies As Health Care's Tech Conversion Accelerates   [Jun-08-18 12:06PM  Investor's Business Daily]
▶ One of the remaining co-op insurers in the country is a Top 100   [Jun-04-18 04:16PM  American City Business Journals]
▶ Evolent Health: 1Q Earnings Snapshot   [May-09-18 06:09PM  Associated Press]
▶ Evolent Health reports 4Q loss   [Feb-27-18 05:57PM  Associated Press]
▶ Premier Health, Virginia company terminate sale of insurance business   [Dec-11-17 01:55PM  American City Business Journals]
▶ Evolent Health drops acquisition deal with Ohio company   [Dec-08-17 03:00PM  American City Business Journals]
▶ Alan Fournier"s 8 Largest Sales of the 3rd Quarter   [Nov-22-17 03:04PM  GuruFocus.com]
▶ Evolent Health reports 3Q loss   [Nov-02-17 06:19PM  Associated Press]
▶ Advisory Board reaches $2.58B deal to sell education, health care businesses   [Aug-30-17 01:51PM  American City Business Journals]

CONTACT US       ASSET ALLOCATION

About X-FIN       Site news       Privacy policy       Terms of use       FAQ

Copyright © X-FIN.com 2005-2018. All rigths reserved.